镓68标记成纤维细胞活化蛋白抑制剂与氟18标记氟代脱氧葡萄糖PET/CT在晚期肺癌评估中的比较
这项前瞻性研究纳入2020年9月至2021年2月间接受镓68标记成纤维细胞活化蛋白抑制剂(68Ga-FAPI)与氟18标记氟代脱氧葡萄糖(18F-FDG)PET/CT两种检查的肺癌患者34例。结果显示,68Ga-FAPI PET/CT在淋巴结、脑、骨和胸膜可疑转移灶的检出数量上多于18F-FDG PET/CT,且原发或复发肿瘤、阳性淋巴结、骨病灶和胸膜病灶的SUVmax与靶本比均更高。结论提示,68Ga-FAPI PET/CT在肺癌分期方面可能优于18F-FDG PET/CT,尤其在脑、淋巴结、骨和胸膜转移的检测方面。
要点
- 68Ga-FAPI PET/CT在脑、淋巴结、骨和胸膜可疑转移灶的检出数量上多于18F-FDG PET/CT。
- 原发或复发肿瘤、阳性淋巴结、骨病灶和胸膜病灶的SUVmax与靶本比,68Ga-FAPI均高于18F-FDG(均P < .01)。
- 脑转移瘤SUVmax在两种方法间无差异(均值9.0 vs 7.4,P = .32),但靶本比68Ga-FAPI更高(均值314.4 vs 1.0,P = .02)。
核心结论
- 68Ga-FAPI PET/CT在肺癌分期方面可能优于18F-FDG PET/CT,尤其在脑、淋巴结、骨和胸膜转移的检测方面。
研究设计与样本
- 前瞻性研究,纳入2020年9月至2021年2月间接受68Ga-FAPI与18F-FDG PET/CT两种检查的肺癌患者34例(中位年龄64岁,四分位距46-80岁;男性20例)。
关键影像表现/征象
- 视觉评估显示,68Ga-FAPI PET/CT与18F-FDG PET/CT在原发肿瘤勾画及肺、肝、肾上腺可疑转移灶检测方面表现相似。
- 68Ga-FAPI PET/CT显示淋巴结可疑转移356处,18F-FDG PET/CT显示320处。
- 68Ga-FAPI PET/CT显示脑可疑转移23处,18F-FDG PET/CT显示10处。
- 68Ga-FAPI PET/CT显示骨可疑转移109处,18F-FDG PET/CT显示91处。
- 68Ga-FAPI PET/CT显示胸膜可疑转移66处,18F-FDG PET/CT显示35处。
诊断标准与关键数值
- 原发或复发肿瘤的代谢性肿瘤体积在两种方法间无差异(均值11.6 vs 10.8,P = .68)。
- 原发或复发肿瘤、阳性淋巴结、骨病灶和胸膜病灶的SUVmax与靶本比,68Ga-FAPI PET/CT均高于18F-FDG PET/CT(均P < .01)。
- 脑转移瘤SUVmax在两种方法间无差异(均值9.0 vs 7.4,P = .32),但靶本比68Ga-FAPI高于18F-FDG(均值314.4 vs 1.0,P = .02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Gallium 68 (68Ga)-labeled fibroblast-activation protein inhibitor (FAPI) has recently been introduced as a promising tumor imaging agent. Purpose To compare 68Ga-FAPI PET/CT with fluorine 18 (18F)-labeled fluorodeoxyglucose (FDG) PET/CT in evaluating lung cancer. Materials and Methods In this prospective study conducted from September 2020 to February 2021, images from participants with lung cancer who underwent both 68Ga-FAPI and 18F-FDG PET/CT examinations were analyzed. The tracer uptakes, quantified by maximum standardized uptake value (SUVmax) and target-to-background ratio (TBR), were compared for paired positive lesions between both modalities using the paired t test or Wilcoxon signed-rank test. Results Thirty-four participants (median age, 64 years [interquartile range: 46-80 years]; 20 men) were evaluated. From visual evaluation, 68Ga-FAPI PET/CT and 18F-FDG PET/CT showed similar performance in the delineation of primary tumors and detection of suspected metastases in the lungs, liver, and adrenal glands. The metabolic tumor volume in primary and recurrent lung tumors showed no difference between modalities (mean: 11.6 vs 10.8, respectively; P = .68). However, compared with 18F-FDG PET/CT, 68Ga-FAPI PET/CT depicted more suspected metastases in lymph nodes (356 vs 320), brain (23 vs 10), bone (109 vs 91), and pleura (66 vs 35). From semiquantitative evaluation, the SUVmax and TBR of primary or recurrent tumors, positive lymph nodes, bone lesions, and pleural lesions at 68Ga-FAPI PET/CT were all higher than those at 18F-FDG PET/CT (all P < .01). Although SUVmax of 68Ga-FAPI and 18F-FDG in brain metastases were not different (mean SUVmax: 9.0 vs 7.4, P = .32), TBR was higher with 68Ga-FAPI than with 18F-FDG (mean: 314.4 vs 1.0, P = .02). Conclusion Gallium 68-labeled fibroblast-activation protein inhibitor PET/CT may outperform fluorine 18-labeled fluorodeoxyglucose PET/CT in staging lung cancer, particularly in the detection of metastasis to the brain, lymph nodes, bone, and pleura. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Jacobson and Van den Abbeele in this issue.
引用
- Wang, Tang, Hu, et al. Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the Evaluation of Advanced Lung Cancer. Radiology. 2022. PMID: 34981976. doi:10.1148/radiol.211424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。